
AstraZeneca Pharmaceuticals LP
NEWS
A quick overview of life science companies scooping up some summer spending money this week.
Regeneron and AstraZeneca are looking to research, develop, and eventually commercialize a new drug that targets GPR75, the gene associated with obesity.
Kodiak Sciences, an ophthalmology-focused biotech company, based in Palo Alto, Calif., reportedly turned down $125 million from Baker Bros after hitting a clinical milestone. The company’s decision to decline this funding was due in part to its “strong balance sheet” and “clinical trial progress.”
The FDA has now approved AstraZeneca’s convenient once-a-week glucose lowering drug for 10 to 17-year-olds with type 2 diabetes.
As COVID-19 begins yet another surge across the U.S., there is some promising news about the effectiveness of vaccines. Here’s a look at some top COVID-19 stories.
It will immediately begin to sell Bylvay to treat patients impacted by PFIC, a rare cholestatic liver disease that often leads to cirrhosis and liver failure within the first ten years of life.
Notably, Koselugo was studied in pediatric populations first, a reversal of the typical development path taken by the majority of drugs.
The company’s technology is designed to attach any off-the-shelf antibody with any payload without the need for modification.
The lawsuit alleges that Ocugen made “materially false and misleading statements” about its operations and compliance policies.
JOBS
IN THE PRESS